Skip to content
AnalystLens

Xylem 8-K Report, Corporate Update (Feb 25, 2026)

Reports
Other Events
Filing Date
Filed February 25, 2026
Period End
February 25, 2026
Security
XYL
In the record · 2016–202610-K1110-Q338-K102

XYL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 102 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Aug ’20Aug ’20
  3. Deal closed8-K · May ’23May ’23
  4. Restructuring8-K · Jan ’25Jan ’25

01—Abstract

Summary

Summary of the 8-K filed February 25, 2026. Cited figures are marked; the original filing is the authoritative source.

Xylem Inc. (XYL) disclosed in a Form 8-K filed under Item 8.01 (Other Events) that its Board of Directors approved on February 25, 2026 a new share repurchase program.

The program authorizes the Company to purchase up to $1.5 billiona of its common stock, $0.01 par value, and has no expiration date. Repurchases may be made through open market purchases or otherwise, in compliance with applicable laws and regulations, at such times and in such amounts as do not exceed the aggregate authorization.

The filing states the program does not obligate Xylem to acquire any particular amount of common stock and may be suspended at any time at the Company's discretion. For investors, the key takeaway is the size and flexibility of the authorization: a $1.5 billionb capacity with no end date gives management discretion over the timing and pace of buybacks, with no commitment to a specific level of repurchases.

02—Key points

Key Highlights

  1. Board approved a new share repurchase program on February 25, 2026
  2. Authorization totals up to $1.5 billion of Xylem common stock ($0.01 par value)
  3. The program has no expiration date
  4. Repurchases may be made via open market purchases or otherwise, subject to applicable laws and regulations
  5. No obligation to repurchase any particular amount of common stock
  6. The program may be suspended at any time at the Company's discretion
  7. Disclosed under Item 8.01 (Other Events); the filing contains no other financial results

03—Questions

Frequently Asked Questions

  1. How large is the new share repurchase authorization?

    The Board authorized Xylem to purchase up to $1.5 billion of its common stock under the new program.

  2. Does the program have an expiration date?

    No. The filing states the new program has no expiration date.

  3. How will Xylem carry out the repurchases?

    Repurchases may be made through open market purchases or otherwise, in compliance with applicable laws and regulations, at times and in amounts that do not exceed the $1.5 billion aggregate authorization.

  4. Is Xylem required to buy back a specific amount of stock?

    No. The filing states the program does not obligate the Company to acquire any particular amount of common stock, and it may be suspended at any time at the Company's discretion.

04—Continue

← View all 8-K filings